drugset
drugset / Trial / NCT02817750

Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation

NCT02817750 ↗

Phase 1 Completed 28 enrolled Biolab Sanus Farmaceutica
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics of the new formulation of zolpidem hemitartarate orodispersible tablet 3.5 mg in male and female healthy volunteers.

Timeline

Start
2017-07-05
Primary completion
2018-02-22
Completion
2018-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule 3.5 mg Oral

Indications

No indication recorded.